Larimar Therapeutics Investor Relations Material
Latest events
Status Update
Larimar Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Larimar Therapeutics Inc
Access all reports
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on its lead compound, CTI-1601, which is currently being developed as a potential treatment for Friedreich's ataxia, a genetic disorder that affects the nervous system and movement. Larimar leverages its proprietary intracellular delivery platform to design fusion proteins aimed at addressing other rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Larimar Therapeutics Inc
Study Update
Larimar Therapeutics Inc
Study Update
Larimar Therapeutics Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
LRMR
Country
🇺🇸 United States